Group 1 - The brain-computer interface sector experienced a decline of 3.34%, ranking among the top losers in the concept sector as of the market close on June 20 [1][2] - Within the brain-computer interface sector, major companies such as Hanwei Technology, Nanjing Panda, and Aipeng Medical saw significant declines, while only two stocks, Haige Communication and ST Huatuo, recorded gains of 1.46% and 1.05% respectively [1][2] - The sector faced a net outflow of 546 million yuan from main funds, with 23 stocks experiencing net outflows, and seven stocks seeing outflows exceeding 30 million yuan [2] Group 2 - Hanwei Technology led the outflow with a net withdrawal of 133 million yuan, followed by Innovative Medical and Tom Cat with outflows of 129 million yuan and 116 million yuan respectively [2][3] - The stocks with the highest net inflows included ST Huatuo, Haige Communication, and Lepu Medical, with inflows of 58.93 million yuan, 35.06 million yuan, and 23.44 million yuan respectively [2][3] - The trading volume for Hanwei Technology was 12.95%, indicating a high turnover rate despite the decline of 6.59% in its stock price [2][3]

特别提示： 证券代码：300003 证券简称：乐普医疗 公告编号：2025-055 债券代码：123108 债券简称：乐普转 2 乐普（北京）医疗器械股份有限公司 关于乐普转 2 恢复转股的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 乐普（北京）医疗器械股份有限公司 债券代码：123108；债券简称：乐普转 2 董事会 转股起止日期：2021 年 10 月 8 日至 2026 年 3 月 29 日 二○二五年六月十八日 暂停转股日期：2025 年 6 月 12 日至 2024 年度权益分派股权登记日（2025 年 6 月 19 日） 恢复转股时间：自 2025 年 6 月 20 日起恢复转股 乐普（北京）医疗器械股份有限公司（以下简称：公司）于 2025 年 6 月 10 日披露了《关于权益分派期间乐普转 2 暂停转股的提示性公告》（公告编号： 2025-052），因公司实施 2024 年年度权益分派，根据《乐普（北京）医疗器械 股份有限公司创业板向不特定对象发行可转换公司债券募集说明书》中"转股价 格的调整方式"条款，公司可转换公司债券乐普转 ...

证券代码：300003 证券简称：乐普医疗 公告编号：2025-056 乐普（北京）医疗器械股份有限公司 关于持股 5%以上股东 2024 年面向专业投资者非公开发行科 技创新可交换公司债券（第一期）换股价格调整的公告 公司股东中国船舶重工集团公司第七二五研究所（洛阳船舶材料研究所）保 证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： "24 船材 EB"调整前的换股价格：21.53 元/股 当公司股票因派送股票股利、转增股本、配股、派送现金股利等情况使公司股票 发生变化时，将按下述公式进行换股价格的调整： 派送股票股利或转增股本：P1=P0/(1+n); 配股 P1=(P0+A×k)/(1+k)； 上述两项同时进行：P1=(P0+A×k)/(1+n+k); 派送现金股利：P1=P0-D; "24 船材 EB"调整后的换股价格：21.39 元/股 "24 船材 EB"本次换股价格调整实施日期：2025 年 6 月 20 日 中国船舶重工集团公司第七二五研究所（洛阳船舶材料研究所）（以下简称 "七 ...

Core Insights - The ablation catheter market in China is expected to grow significantly due to the rising incidence of cardiovascular diseases and the increasing demand for medical resources, with a projected market size of 7.392 billion yuan in 2024, representing a year-on-year growth of 10.28% [1][7][24] - The prevalence of arrhythmias is showing a notable trend towards younger demographics, with an estimated 12.37 million hospital visits for arrhythmias in 2024, marking a 21% increase from 2023 [1][5][24] Industry Definition and Classification - Ablation catheters are slender, flexible interventional devices inserted into specific areas of the heart via blood vessels, designed to release energy to create controlled damage, eliminating abnormal electrical signals that cause arrhythmias [2][3] Current Industry Development - The ablation catheter industry is experiencing rapid growth, supported by policy backing and increased per capita medical spending, with a significant rise in the number of related procedures due to an aging population and improved healthcare awareness [5][13] - The number of registered ablation catheter products in China has reached 60 from 2015 to 2024, with a notable increase in registrations for radiofrequency ablation catheters [9][24] Competitive Landscape - The market is dominated by multinational companies such as Johnson & Johnson and Abbott, which have established strong brand recognition and competitive advantages through long-term investments [15][24] - Domestic companies like Microelectrophysiology and Huatai Medical are emerging as significant players, with Microelectrophysiology achieving over 4,000 procedures in 2024 and Huatai Medical completing over 15,000 procedures, reflecting substantial growth in market share [18][22] Industry Trends - The high-end market remains dominated by international giants, but domestic companies are expected to accelerate their growth through technological collaboration and policy support, leading to increased market space for ablation catheters [24]

Core Points - The company has announced a cash dividend distribution plan for its shareholders, with a total cash dividend of 248,858,399.39 RMB, which translates to 1.350000 RMB per 10 shares held [1][2][5] - The total share capital of the company is 1,880,611,251 shares, and after deducting the repurchased shares of 37,215,700, the base for the dividend distribution is 1,843,395,551 shares [1][2] - The dividend distribution will not include stock dividends or capital reserve transfers, and any undistributed profits will be carried forward to future distributions [1][2] Dividend Distribution Details - The cash dividend of 1.350000 RMB per 10 shares is applicable to all shareholders, with specific tax considerations for different types of investors [2][5] - The dividend distribution will be executed on June 20, 2025, with the record date set for June 19, 2025 [3][4] - The reference price for the ex-dividend date is calculated by subtracting the per-share cash dividend from the closing price on the trading day before the ex-dividend date [5] Shareholder Information - The dividend distribution will be made to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shenzhen Branch as of the record date [3] - The company will bear all legal responsibilities for any shortfall in cash dividends due to a decrease in shares held by shareholders during the distribution application period [4] Additional Information - The company has provided contact details for inquiries regarding the dividend distribution [8] - The announcement was made on June 13, 2025, by the company's board of directors [6]

证券代码：300003 证券简称：乐普医疗 公告编号：2025-053 乐普（北京）医疗器械股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次权益分派期间，公司可转换公司债券乐普转 2（债券代码：123108） 已暂停转股，截至本公告披露日，公司总股本为 1,880,611,251 股。 1、乐普（北京）医疗器械股份有限公司（以下简称：公司）2024 年年度权 益分派方案经 2025 年 5 月 15 日召开的 2024 年年度股东大会审议通过； 2、自本次权益分派方案披露至实施期间，公司总股本因可转换公司债券乐 普转 2 部分转股而发生变动，截至本公告披露日，公司总股本由 2025 年 3 月 31 日的 1,880,611,082 股增至 1,880,611,251 股； 3、本次实施的权益分配方案与公司股东大会审议通过的方案一致； 4、本次实施权益分派方案距离股东大会审议通过的时间未超过两个月。 1 二、权益分派方案 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》"第二 ...

| 证券代码：300003 | 证券简称：乐普医疗 | 公告编号：2025-054 | | --- | --- | --- | | 债券代码：123108 | 债券简称：乐普转 2 | | 乐普（北京）医疗器械股份有限公司 关于可转债乐普转 2 转股价格调整的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 债券代码：123108 债券简称：乐普转 2 调整前"乐普转 2"转股价格为：27.92 元/股 调整后"乐普转 2"转股价格为：27.79 元/股 转股价格调整生效日期：2025 年 6 月 20 日 一、转股价格调整的相关规定 经中国证券监督管理委员会出具的《关于同意乐普（北京）医疗器械股份有 限公司向不特定对象发行可转换公司债券注册的批复》（证监许可〔2021〕741 号）核准，乐普（北京）医疗器械股份有限公司（以下简称"公司"）于 2021 年 3 月 30 日向不特定对象发行了 1,638.00 万张可转换公司债券（以下简称"可 转债"），每张面值 100 元，发行总额 163,800.00 万元。 根据《乐普（北京）医疗器械股份 ...

Core Insights - The total margin financing balance for the ChiNext market reached 344.136 billion yuan, marking a continuous increase for six trading days, with a cumulative increase of 5.784 billion yuan during this period [1][2]. Margin Financing Balance Overview - As of June 10, 2025, the total margin financing balance was 345.070 billion yuan, with an increase of 0.321 billion yuan from the previous trading day [2]. - The margin financing balance specifically was 344.136 billion yuan, which increased by 0.342 billion yuan from the previous day [2]. Individual Stock Performance - During the period of increasing margin financing, 559 stocks saw an increase in their financing balances, with 56 stocks experiencing an increase of over 20% [2]. - The stock with the highest increase in financing balance was Dahongli, which saw an increase of 111.16%, bringing its latest financing balance to 56.0291 million yuan [3]. - Conversely, 374 stocks experienced a decrease in their financing balances, with 42 stocks declining by over 10%. The largest decrease was seen in Lulian Technology, which dropped by 38.36% [3]. Sector Performance - Stocks with financing balance increases of over 20% were primarily concentrated in the pharmaceutical, machinery, and basic chemical industries, with 14, 7, and 7 stocks respectively [5]. Market Performance - Stocks with financing balance increases of over 20% averaged a rise of 12.00%, outperforming the ChiNext index. Notable gainers included Kangli Source, Changshan Pharmaceutical, and Xice Testing, with increases of 64.82%, 34.93%, and 33.42% respectively [5]. - The largest increases in financing balances by amount were recorded by Sifang Jingchuang (1.305 billion yuan), followed by Juguang Technology (300 million yuan) and Lepu Medical (252 million yuan) [5].

证券代码：300003 证券简称：乐普医疗 公告编号：2025-052 债券代码：123108 债券简称：乐普转 2 乐普（北京）医疗器械股份有限公司 关于权益分派期间乐普转 2 暂停转股的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 债券代码：123108 债券简称：乐普转 2 转股起止时间：2021 年 10 月 8 日至 2026 年 3 月 29 日 暂停转股时间：2025 年 6 月 12 日至 2024 年度权益分派股权登记日 恢复转股时间：公司 2024 年度权益分派股权登记日后的第一个交易日 乐普（北京）医疗器械股份有限公司（以下简称：公司）将于近日实施 2024 年度权益分派，根据《乐普（北京）医疗器械股份有限公司创业板向不特定对象 发行可转换公司债券募集说明书》中"转股价格的调整方式"条款的规定（详见 附件），自 2025 年 6 月 12 日起至本次 2024 年度权益分派股权登记日止，公司 可转换公司债券乐普转 2（债券代码：123108；债券简称：乐普转 2）将暂停转 股，公司将在本次权益分派股权登记日后的第 ...

Company Overview - Lepu Medical's closing price on June 10 was 13.47 yuan, with an increase of 4.10%, resulting in a rolling price-to-earnings (PE) ratio of 176.40 times and a total market capitalization of 25.332 billion yuan [1] - The company's main business includes medical devices, pharmaceuticals, medical services, and health management [1] Financial Performance - In the first quarter of 2025, Lepu Medical reported operating revenue of 1.736 billion yuan, a year-on-year decrease of 9.67%, and a net profit of 379 million yuan, down 21.44% year-on-year, with a gross profit margin of 64.03% [1] Industry Comparison - The average PE ratio for the medical device industry is 51.00 times, with a median of 37.03 times, placing Lepu Medical at the 113th position in the industry ranking [1][2] - The industry average market capitalization is 10.870 billion yuan, while the median is 4.980 billion yuan [2] Capital Flow - On June 10, Lepu Medical experienced a net inflow of main funds amounting to 176.6142 million yuan, with a total inflow of 174.9574 million yuan over the past five days [1]